Tegaserod, an investigational serotonin receptor agonist, provides global relief of the symptoms of constipation-predominant irritable bowel syndrome (IBS) with an acceptable incidence of adverse events, according to the results of meta-analysis of four phase III trials presented at Digestive Disease Week in San Francisco.
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.